Kyle Eliason, MD
Gastroenterology · Ogden, UTNPI 1336374511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,220 of the $127,713 with a category attached, or 80.8%. 21 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 35.5% of the total. Among gastroenterology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $430.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$45K
- AbbVie$40K
- Sanofi$37K
- Boston Scientific$3K
- Merit Medical Systems Inc$725
- Bristol Myers Squibb$394
- plus $2K from 15 others
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$7001%
- Speaking & faculty fees$103,22081%
- Travel & lodging$16,14113%
- Food & beverage$7,6446%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 49 | $45,313 |
| AbbVie | 96 | $39,980 |
| Sanofi | 41 | $37,177 |
| Boston Scientific | 44 | $2,592 |
| Merit Medical Systems Inc | 2 | $725 |
| Bristol Myers Squibb | 39 | $394 |
| E.r. Squibb & Sons, L.L.C. | 2 | $257 |
| Conmed Corporation | 2 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $145 |
| Endogastric Solutions, Inc | 4 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $144 |
| Dova Pharmaceuticals | 1 | $123 |
| Gilead | 1 | $122 |
| Intercept Pharmaceuticals, Inc. | 1 | $114 |
| Intuitive Surgical | 1 | $82 |
| Pfizer | 1 | $52 |
| Johnson & Johnson | 2 | $37 |
| Pacira Pharmaceuticals Incorporated | 1 | $36 |
| Fujifilm Healthcare Americas Corporation | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$80,663
- Creon$28,784
- LINZESS$8,548
- RESOLUTION CLIP$585
- GENERAL POLYPECTOMY$519
- ZEPOSIA$257
- DOPTELET$123
- XIFAXAN$122
- Epclusa$122
- CONMED BILIARY$118
- Rinvoq$114
- OCALIVA$114
- Skyrizi$107
- Humira$103
How this compares
$127,713 in reported general payments places this provider in the 95th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 73 | $1,955,224 |
| EntyvioVedolizumab | 17 | $145,189 |
| Dupixent PenDupilumab | 12 | $88,721 |
| XifaxanRifaximin | 24 | $79,364 |
| LinzessLinaclotide | 103 | $60,500 |
| TrulancePlecanatide | 33 | $21,127 |
| EliquisApixaban | 24 | $18,682 |
| ErythromycinErythromycin Base | 25 | $18,352 |
| Mesalamine | 34 | $14,953 |
| Colestipol Hcl | 172 | $11,863 |
| Omeprazole | 486 | $9,982 |
| Ursodiol | 61 | $4,322 |
| Dexlansoprazole DrDexlansoprazole | 26 | $4,131 |
| Azathioprine | 58 | $3,375 |
| Colesevelam Hcl | 12 | $3,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $37 | $1,955,22473 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $145 | $145,18917 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $144 | $100,49157 claims |
| AbbVieLinzess | $39,980 | $60,500103 claims |
| PfizerEliquis | $52 | $18,68224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 122 gastroenterology providers in Utah.
Other gastroenterology in Ogden
- Chad GonzalesOgden$25K
- Eric EliasonOgden$18K
- Jeffrey PooleOgden$7K
- Joshua VandersteenOgden$7K
- Samuel FrostOgden$4K
- Robert ZieglerOgden$3K
- Terry BoxSalt Lake City$302K
- Richard GilroySalt Lake City$192K
- Umaprasanna KarnamRiverton$120K
- Kathryn PetersonSalt Lake City$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.